[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mycoplasma-pneumoniae\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mycoplasma-pneumoniae":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100541087","a-trial-of-placebo-versus-macrolide-for-mycoplasma-pneumoniae-childhood-pneumonia-mythic-study-100541087",false,"NCT06325293","A Trial of Placebo Versus Macrolide for Mycoplasma Pneumoniae Childhood Pneumonia: MYTHIC Study","A Randomized Controlled Non-inferiority Trial of Placebo Versus Macrolide Antibiotics for Mycoplasma Pneumoniae Infection in Children With Community-acquired Pneumonia - the MYTHIC Study","MYTHIC","Inclusion criteria for screening phase:\n\n* Children aged 3-17 years (from 3rd up to 18th birthday) presenting to the emergency department (ED) who will be managed ambulatory or will be admitted to general ward.\n* Clinical diagnosis of CAP:\n\n  1. Diagnosis defined as the treating physician's documented diagnosis of CAP; AND\n  2. Fever ≥38.0°C (measured by any method \\[i.e., ear, axillary, rectal, or forehead site\\] in the ED or via parent report observed in the last 24h); AND\n  3. Tachypnea (defined as respiratory rate (RR) above age-specific reference value) during the assessment in ED (triage or clinical examination).\n* Written screening consent for participation in screening phase signed by parents\u002Flegal guardians and the patient if ≥14 years of age.\n\nAdditional inclusion criteria for intervention phase:\n\n* Positive Mp screening test result with the Mp IgM lateral flow assay (LFA) (grade 2 or 3).\n* Written informed consent for participation in intervention phase signed by parents or legal guardians and the patient if ≥14 years of age.\n\nExclusion criteria:\n\nExclusion criteria for screening phase:\n\n• None.\n\nExclusion criteria for intervention phase:\n\n* Contraindication to azithromycin: Documented allergy to azithromycin; cardiovascular disease, including bradycardia, arrhythmias, and\u002For QT-interval prolongation\\*; myasthenia gravis.\n\n  \\*Co-medication with arrhythmogenic or QT-interval-prolonging drug (www.qtdrugs.org) is no exclusion criteria but will be discussed with the local investigators and\u002For trial management team (TMT).\n* Underlying comorbidities: Cystic fibrosis or other chronic lung disorders (excluding asthma), primary or secondary immunodeficiency, sickle-cell anemia, or severe cerebral palsy.\n* History of recurrent pneumonia (two or more episodes) or severe pneumonia (ICU admission or complications of CAP such as lung abscess, effusion, and empyema) in lifetime.\n* Antibiotic treatment against Mp within the previous 7 days, including macrolides, tetracyclines, or fluoroquinolones.\n* Referral to ICU directly from the ED.\n* Inability to take oral medication.\n* Parents are unlikely to reliably complete follow up (FUP) visits and questionnaires (e.g., due to language barriers or living far from the study site).","ALL","3 Years","17 Years",{"count":21,"type":22},376,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to compare a placebo (a look-alike substance that contains no active drug) with a commonly used antibiotic in children with Mycoplasma pneumoniae (a specific bacterium) induced community-acquired pneumonia. The main question it aims to answer is:\n\nIs antibiotic treatment needed in Mycoplasma pneumoniae (a specific bacterium) induced pneumonia?\n\nParticipants will receive either a placebo or a antibiotic treatment and track their symptoms and vital signs until they are healthy.\n\nResearchers will then compare the length of symptoms between the placebo and the antibiotic group.",[28,29,30],"Community Acquired Pneumonia in Children","Mycoplasma Pneumoniae","Mycoplasma Pneumoniae Pneumonia",[32,33,34,35,36,37,38,39],"Mycoplasma pneumoniae","community-acquired pneumonia","randomized controlled trial","Investigator Initiated Clinical Trial (IICT)","Paediatric pneumonia","children","placebo","macrolides","RECRUITING","2026-04-29",{"date":43,"type":44},"2026-05-05","ACTUAL",{"date":46,"type":44},"2025-01-28",{"date":48,"type":22},"2028-12-31",{"name":50,"class":51},"Christoph Berger","OTHER",13,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":67,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100616486","phase-4-doxycycline-vs-macrolide-for-mrmp-domino-100616486","NCT07306234","Doxycycline vs. Macrolide for MRMP (DOMINO)","Efficacy and Safety of Doxycycline Versus Macrolides for Mycoplasma Pneumoniae Infection in Children (DOMINO): A Protocol for a Multicenter, Randomized, Open-Label, Superiority Trial","DOMINO","Inclusion Criteria:\n\n* Age: 3 to 17 years at the time of enrollment.\n* Diagnosis: Clinically diagnosed CAP characterized by respiratory symptoms (e.g., fever, cough, auscultatory findings) and chest X-ray confirming pulmonary infiltrates.\n* Pathogen: Confirmed MP M. pneumoniae infection via PCR OR strongly suspected infection based on clinical features and epidemiological grounds (e.g., outbreaks among classmates, poor response to prior non-macrolide antibiotics).\n* Resistance: Suspected macrolide-resistant M. pneumoniae (MRMP) infection (e.g., during a reported local epidemic of MRMP).\n* Timing: Ability to register and initiate the study drug within 72 hours of symptom onset.\n\nExclusion Criteria:\n\n* Prior use of tetracyclines, macrolides, or quinolones for the current illness.\n* Complicated pneumonia (e.g., necrosis, empyema, lung abscess) or severe pneumonia requiring immediate intensive care or exhibiting hypoxia (SpO₂ \\\u003C90%).\n* Hypersensitivity or contraindications to macrolides or tetracyclines.\n* Severe immunocompromised state or severe underlying lung disease.\n* Severe hepatic impairment (AST\u002FALT \\>3x upper limits) or severe renal impairment.",{"count":62,"type":22},208,[64],"PHASE4","The goal of this clinical trial is to learn if doxycycline works to treat pneumonia in children. It focuses on children with Mycoplasma pneumoniae infection that may not respond to standard medicines. The main questions it aims to answer are:\n\n* Does doxycycline stop fevers faster than azithromycin?\n* Is doxycycline safe for children, specifically regarding tooth color changes?\n\nResearchers will compare doxycycline to azithromycin to see if doxycycline works better to treat this type of pneumonia.\n\nParticipants will:\n\n* Take either doxycycline or azithromycin by mouth for 7 to 14 days.\n* Check their body temperature to see when their fever goes away.\n* Visit the hospital to check for any medical problems.\n* Have their teeth checked for color changes 28 days after starting the medicine.",[29,30],[32,68,69],"Macrolide resistance","Children","NOT_YET_RECRUITING","2025-12-24",{"date":73,"type":44},"2025-12-29",{"date":75,"type":22},"2026-03-01",{"date":77,"type":22},"2029-02-28",{"name":79,"class":51},"Young June Choe",14]